Results 11 to 20 of about 46,900 (298)
DPP4 (dipeptidyl-peptidase 4) [PDF]
Atlas of Genetics and Cytogenetics in Oncology and Haematology, 2013 Review on DPP4 (dipeptidyl-peptidase 4), with data on DNA, on the protein encoded, and where the gene is implicated.
Ohnuma, K, Morimoto, C
openaire +3 more sources
Journal of Clinical Medicine, 2022 Dipeptidyl peptidase 4 (DPP-4) is a novel adipokine and may be involved in the association between adipose tissue and metabolic syndrome. We investigated DPP-4 and adiponectin levels in the serum, subcutaneous adipose tissue (SAT), and epicardial adipose tissue (EAT), and their relationship with preoperative factors, as well as comparing the DPP-4 ...
Ikuko Shibasaki +15 more
openaire +3 more sources
Identification of a Novel Scaffold for Inhibition of Dipeptidyl Peptidase-4
Journal of Computational Biology, 2019 Dipeptidyl peptidase-4 (DPP-4) is considered a major drug target for type 2 diabetes mellitus (T2DM). In addition to T2DM, a regulatory role of DPP-4 was also found in cardiovascular diseases. Existing DPP-4 inhibitors have been reported to have several adverse effects.
Avinash Mishra +5 more
openaire +6 more sources
Novel Dipeptidyl Peptidase-4–Inhibiting Peptide Derived From β-Lactoglobulin
Journal of Pharmacological Sciences, 2011 .: Trypsin-treated β-lactoglobulin significantly decreased the glucose level after an oral glucose tolerance test using mice. We performed the present study to identify the active peptide inhibiting dipeptidyl peptidase-4 from trypsin-treated β ...
Masayuki Uchida +2 more
doaj +2 more sources
BMC Endocrine Disorders, 2021 Background Bullous pemphigoid is the most common bullous chronic autoimmune skin disease. Recent studies have suggested dipeptidyl-peptidase 4 inhibitors as possible predisposing agents of bullous pemphigoid.
Vaia Lambadiari +10 more
doaj +2 more sources
The role of dipeptidyl peptidase - 4 inhibitors in diabetic kidney disease
Frontiers in Immunology, 2015 Despite major advances in the understanding of the molecular mechanisms that underpin the development of diabetic kidney disease, current best practice still leaves a significant proportion of patients with end stage kidney disease requiring renal ...
Usha ePanchapakesan, Carol ePollock
doaj +2 more sources
Navigating the chemical space of dipeptidyl peptidase-4 inhibitors
Drug Design, Development and Therapy, 2015 Watshara Shoombuatong,1 Veda Prachayasittikul,1,2 Nuttapat Anuwongcharoen,1 Napat Songtawee,1 Teerawat Monnor,1 Supaluk Prachayasittikul,1 Virapong Prachayasittikul,2 Chanin Nantasenamat1,2 1Center of Data Mining and Biomedical Informatics, 2Department ...
Shoombuatong W +7 more
doaj +1 more source
The purification and characterisation of novel dipeptidyl peptidase IV-like activity from bovine serum [PDF]
, 2004 The discovery of a potentially novel proline-specific peptidase from bovine serum is presented which is capable of cleaving the dipeptidyl peptidase IV (DPIV) substrate Gly-Pro-MCA.
Buckley, Seamus J. +3 more
core +1 more source
Solvent and thermal stability, and pH kinetics, of proline-specific dipeptidyl peptidase IV-like enzyme from bovine serum [PDF]
, 2007 Proline-specific dipeptidyl peptidase-like (DPP IV; EC 3.4.14.5) activity in bovine serum has attracted little attention despite its ready availability and the paucity of useful proline-cleaving enzymes.
Ruth, Deborah M. +4 more
core +1 more source
, 2022 Dipeptidyl-peptidase-4 is a multifunctional ectoenzyme, which is implicated with hyperglycemic pathophysiology. Therefore, dipeptidyl-peptidase-4 inhibitors could be used as an attractive therapeutic strategy in blood-glucose homeostasis to attenuate the
Kajal Chakraborty (2629708) +2 more
core +1 more source